☆ 4.6 Article

Post-Neoadjuvant Treatment Strategies in Breast Cancer

CANCERS (2022)

Related references

Note: Only part of the references are listed.

Article Oncology

Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

Christina Yau et al.

Summary: This study analyzed data from multiple independent cohorts to evaluate the relationship between residual cancer burden (RCB) and long-term prognosis in different subtypes of breast cancer. The results showed that higher RCB score was significantly associated with worse event-free survival in all breast cancer subtypes. The study suggests considering the evaluation of RCB as part of standard pathology reporting.

LANCET ONCOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

P. Schmid et al.

Summary: The addition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab after surgery significantly prolonged event-free survival in patients with early triple-negative breast cancer.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Prospective Evaluation of Response Outcomes of Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer

A. Ashok et al.

Summary: Breast cancer is a global health problem and is the most common cancer among Indian women. Locally advanced breast cancer is common in developing countries and requires multimodality therapy and coordinated treatment planning. Neoadjuvant chemotherapy is effective in downstaging tumors, although complete clinical response may be lower.

CUREUS JOURNAL OF MEDICAL SCIENCE (2022)

Add to Collection

Article Oncology

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

N. Harbeck et al.

Summary: Adjuvant abemaciclib combined with endocrine therapy significantly improved invasive disease-free survival in patients with early breast cancer, with an acceptable safety profile. Ki-67 index was prognostic but did not affect the benefits of abemaciclib. The robust treatment benefit of abemaciclib extended beyond the planned 2-year treatment period.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Oncology

Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment by an intelligent vacuum-assisted biopsy

Andre Pfob et al.

Summary: The study developed and tested multivariate algorithms to accurately identify breast cancer patients without residual cancer after neoadjuvant treatment. The neural network showed the best performance with a specificity ranging from 65.2% to 67.2% in both test and external validation datasets.

EUROPEAN JOURNAL OF CANCER (2021)

Add to Collection

Review Oncology

Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox

Peter Dubsky et al.

Summary: An international consortium was established to provide clinical guidance and tools for the technical management of patients with early-stage breast cancer through discussions and consensus meetings. During the meeting, 42% of statements reached a consensus, 38% were supported by the majority, and 21% did not reach a decision.

LANCET ONCOLOGY (2021)

Add to Collection

Article Obstetrics & Gynecology

AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update

Michael Friedrich et al.

Summary: The evolution of surgical procedures in breast cancer treatment focuses on optimizing systemic therapy and surgical methods, especially as neoadjuvant chemotherapy becomes increasingly important. Targeted axillary dissection and other methods aim to reduce the false negative rate in surgical axillary staging.

GEBURTSHILFE UND FRAUENHEILKUNDE (2021)

Add to Collection

Article Obstetrics & Gynecology

AGO Algorithms for the Treatment of Breast Cancer: Update 2021

Andreas Schneeweiss et al.

Summary: The therapy options presented in the algorithms are based on current AGO recommendations and may not cover all evidence-based treatment choices. Patient-specific factors and preferences need to be considered, and the algorithms only include drugs available in Germany.

GEBURTSHILFE UND FRAUENHEILKUNDE (2021)

Add to Collection

Article Multidisciplinary Sciences

Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy

Kartik Anand et al.

Summary: The combination therapy of everolimus and cisplatin aimed to improve the rate of pathologic response in TNBC patients, with a 23% response rate observed in those achieving RCB-I during surgery.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Oncology

Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial

Sibylle Loibl et al.

Summary: The study investigated the efficacy of palbociclib in breast cancer patients with residual invasive disease after neoadjuvant chemotherapy, showing that palbociclib in addition to endocrine therapy did not improve invasive disease-free survival. Some related serious adverse events were reported, but no significant difference between treatment arms.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Utility of the CPS plus EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy

Frederik Marme et al.

Summary: In triple negative breast cancer, pathological complete response is associated with superior survival. The CPS + EG system provides refined estimate of prognosis but is less superior compared to pathological stage. Pathological complete response remains the strongest and most clinically useful prognostic factor after neoadjuvant chemotherapy.

EUROPEAN JOURNAL OF CANCER (2021)

Add to Collection

Article Oncology

Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131

Ingrid A. Mayer et al.

Summary: The study showed that adjuvant platinum agents do not improve outcomes in patients with residual invasive disease (RD) of basal subtype TNBC post- NAC, and are associated with more severe toxicity compared with capecitabine. Participants had a lower than expected 3-year invasive disease-free survival (iDFS) regardless of study treatment, highlighting the need for better therapies in this high-risk population.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials

Carsten Denkert et al.

Summary: The development of anti-HER2 antibody-drug conjugates provides new therapeutic options for breast cancer patients, including those with low expression of HER2. HER2-low-positive breast cancer is a distinct subtype with specific biology, showing differences in response to therapy and prognosis, especially in hormone receptor-negative tumors.

LANCET ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

Andrew N. J. Tutt et al.

Summary: In patients with high-risk, HER2-negative early breast cancer and germline BRCA1 or BRCA2 pathogenic or likely pathogenic variants, adjuvant olaparib after completion of local treatment and neoadjuvant or adjuvant chemotherapy was associated with significantly longer survival free of invasive or distant disease than placebo. Olaparib had limited effects on global patient-reported quality of life.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Oncology

Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer A Phase 2 Randomized Clinical Trial

Thomas Hatschek et al.

Summary: A randomized phase 2 trial in Sweden compared standard neoadjuvant therapy with combination DTP to T-DM1 monotherapy in ERBB2-positive breast cancer patients, showing no significant difference in treatment outcomes between the two groups.

JAMA ONCOLOGY (2021)

Add to Collection

Review Oncology

Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges

J. Heil et al.

ANNALS OF ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab for Early Triple-Negative Breast Cancer

Peter Schmid et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Meeting Abstract Oncology

PREDIX HER2 trial: Event-free survival and pathologic complete response in clinical subgroups and stromal TILs levels

T. Hatschek et al.

ANNALS OF ONCOLOGY (2020)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Role of MRI to Assess Response to Neoadjuvant Therapy for Breast Cancer

Beatriu Reig et al.

JOURNAL OF MAGNETIC RESONANCE IMAGING (2020)

Add to Collection

Article Oncology

Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial

Milan Radovich et al.

JAMA ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

Elizabeth A. Mittendorf et al.

LANCET (2020)

Add to Collection

Article Oncology

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020

Nina Ditsch et al.

BREAST CARE (2020)

Add to Collection

Article Oncology

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

S. Loibl et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Article Oncology

Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study

Sara A. Hurvitz et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Review Oncology

Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalation

Giacomo Pelizzari et al.

CANCER TREATMENT REVIEWS (2019)

Add to Collection

Article Medicine, General & Internal

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

G. von Minckwitz et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Review Oncology

Individualization of post-mastectomy radiotherapy and regional nodal irradiation based on treatment response after neoadjuvant chemotherapy for breast cancer

David Krug et al.

STRAHLENTHERAPIE UND ONKOLOGIE (2018)

Add to Collection

Review Oncology

Neoadjuvant chemotherapy for breast cancer-background for the indication of locoregional treatment

David Krug et al.

STRAHLENTHERAPIE UND ONKOLOGIE (2018)

Add to Collection

Article Medicine, General & Internal

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy

N. Masuda et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Oncology

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel

U. A. Nitz et al.

ANNALS OF ONCOLOGY (2017)

Add to Collection

Article Oncology

CREATE-X a role for capecitabine in early-stage breast cancer: an analysis of available data

Jo Anne Zujewski et al.

NPJ BREAST CANCER (2017)

Add to Collection

Article Oncology

Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29)

G. von Minckwitz et al.

EUROPEAN JOURNAL OF CANCER (2016)

Add to Collection

Article Oncology

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Arlene Chan et al.

LANCET ONCOLOGY (2016)

Add to Collection

© Peeref 2019-2024. All rights reserved.